Michael R. Laing

Michael R. Laing is a registered patent attorney at Andrus Intellectual Property Law. Michael uses his background in mechanical and civil engineering to manage complex patent and IP litigation matters. He represents technology companies in a broad range of industries, including biotechnology, pharmaceutical, life sciences, medical devices, consumer products, manufacturing, software and digital media, entertainment, sports, and gaming. His experience extends to all stages of litigation, including due diligence, initial case assessment, client counseling, discovery, mediation, arbitration, summary judgment, trial, and appeals.

In addition to his litigation practice, Michael serves clients in U.S. and international patent prosecution and counsels clients on all patent, trademark, and copyright concerns. He provides infringement, novelty, and right-to-use opinions in a wide variety of technology areas.

Michael was selected for inclusion in The Best Lawyers in America©: Ones to Watch 2026 and was included in the Super Lawyers - Rising Stars Editions from 2020 to the present. 

Education and Experience

Michael received a bachelor of science degree in civil engineering from Marquette University in 2012. He received his juris doctor degree from Marquette University Law School in 2017, where he was the Managing Editor of the Marquette Law Review.

Prior to joining the firm, Michael was with an AmLaw 50 law firm. Before becoming an attorney, he spent several years as a bridge engineer for the world’s largest engineering design firm, gaining valuable industry experience that informs his counsel to clients.

Memberships

• American Bar Association
• American Intellectual Property Law Association
• Federal Circuit Bar Association
• Thomas E. Fairchild American Inn of Court

Representative Cases

• U.S. Water Services, Inc., et al. v. Novozymes A/S, et al. (W.D. Wis.) (represented plaintiff in patent infringement litigation involving phytase enzymes).
• Kurita America Inc. v. BASF Corp., et al. (N.D. Ill.) (represented plaintiff in patent infringement litigation involving phytase enzymes).
• Direct Supply, Inc. v. Park Supply of America, Inc. (E.D. Wis.) (represented plaintiff in trademark infringement litigation).
• Skillz Platform, Inc. v. AviaGames Inc. (N.D. Cal.) (represented defendant in patent infringement litigation involving real-money mobile gaming platforms).
• H-E-B, LP v. Wadley Holdings, LLC, dba nICE Coolers et al. (W.D. Tex.) (represented plaintiff in patent infringement litigation involving portable coolers).
• Krispy Krunchy Foods LLC v. Silco LLC (E.D. Wis.) represented plaintiff in trademark infringement litigation).
• VoIP-Pal.com, Inc. v. T-Mobile USA, Inc. (W.D. Tex.) (represented defendant in patent infringement litigation involving telecommunications technology).
• Illinois Tool Works, Inc. v. Chicago Laminating, Inc. (N.D. Ill.) (represented defendant in patent infringement litigation involving lamination processes).
• Johnson Health Tech Co., Ltd. v. Peloton Interactive, Inc. (W.D. Wis., P.T.A.B.) (represented plaintiff in patent infringement litigation involving exercise equipment).
• A.O. Smith Corp. v. Rheem Manufacturing Co. (D. Del., N.D. Ga.) (represented plaintiff in patent infringement litigation involving water heaters).
• MiBev Creations, LLC v. A.O. Smith Water Treatment (North America), Inc. (W.D. Tex.) (represented defendant in patent infringement litigation involving filtered water dispensers).
• Allele Biotech. and Pharm., Inc. v. Regeneron Pharm., Inc. (S.D.N.Y.) (represented plaintiff in patent infringement litigation involving isolated nucleic acid sequences encoding monomeric green/yellow fluorescent proteins).
• Novo Nordisk Inc., et al. v. Mylan Pharm. Inc., et al. (D. Del., N.D.W. Va.) (represented defendant in multi-district patent infringement litigation involving Ozempic®, semaglutide).
• AstraZeneca AB, et al. v. Mylan Pharm. Inc., et al. (Fed. Cir., D. Del., N.D.W. Va.) (represented defendant in patent infringement litigation involving Symbicort®, budesonide/formoterol).
• Biogen International GMBH, et al. v. Mylan Pharm. Inc., et al. (Fed. Cir., D. Del., N.D.W. Va., P.T.A.B.) (represented defendant in patent infringement litigation involving Tecfidera®, dimethyl fumarate).
• Novartis Pharm. Corp. v. Accord Healthcare Inc., et al. (Fed. Cir., D. Del.) (represented defendant in patent infringement litigation involving Gilenya®, fingolimod).
• Horizon Pharma, Inc., et al. v. Mylan Pharm. Inc., et al. (Fed. Cir., D.N.J., P.T.A.B.) (represented defendant in patent infringement litigation involving Vimovo®, naproxen/esomeprazole).
• Otsuka Pharm. Co., et al. v. Mylan Labs. Ltd., et al. (D. Del.) (represented defendant in patent infringement litigation involving Abilify®, aripiprazole).
• Merck Sharp & Dohme B.V., et al. v. Mylan Pharm. Inc., et al. (D. Del., N.D.W. Va.) (represented defendant in patent infringement litigation involving Bridion®, sugammadex).
• Horizon Pharma USA, Inc., et al. v. Mylan Pharm. Inc., et al. (D.N.J.) (represented defendant in patent infringement litigation involving Nexium®, esomeprazole).
• Celgene Corp. v. Dr. Reddy’s Labs. Inc., et al. (D.N.J.) (represented defendant in patent infringement litigation involving Pomalyst®, pomalidomide).
• Celgene Corp. v. Dr. Reddy’s Labs. Inc., et al. (D.N.J.) (represented defendant in patent infringement litigation involving Revlimid®, lenalidomide).
• Apotex Inc. vs Mylan Specialty L.P. (Del. Sup. Ct.) (represented defendant in complex commercial litigation involving Dymista®, azelastine/fluticasone).
• Avion Pharm., LLC, et al. v. Granules Pharm., Inc. (D. Del.) (represented plaintiff in patent infringement litigation involving Gloperba®, colchicine).
• Pacira Pharm., Inc., et al. v. eVenus Pharm. Labs. Inc., et al. (D.N.J.) (represented plaintiff in patent infringement litigation involving Exparel®, bupivacaine liposome injectable suspension).